Moderna Vaccine Hero Video

 

 

 

The George Washington University (GW) is playing an important role in a historic global effort to rapidly develop and test investigational vaccines that protect against the novel coronavirus and its disease, COVID-19. In July 2020, GW began its participation in a late-stage (Phase 3) study of Moderna’s mRNA vaccine as a clinical research site. Because of its long track record in conducting vaccine research and clinical vaccine trials, as well as its extensive community partnerships, the university was one of nearly 100 clinical research sites in the U.S. selected to test potential COVID-19 vaccines as part of the COVID-19 Prevention Network, established by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).  

On Nov. 30, 2020, Moderna reported that the vaccine's efficacy against COVID-19 was 94.1% and filed with the U.S. Food and Drug Administration for Emergency Use Authorization.

 

349

volunteers enrolled in GW's clinical trial to test Moderna's vaccine

50%

of GW's enrolled volunteers came from communities of color

25%

of GW's enrolled volunteers had a comorbidity such as heart disease, severe obesity or diabetes

26%

of GW's enrolled volunteers were over the age of 65

 

 



 

Hear from some of those involved in the Moderna vaccine clinical trial at GW.

 


 

 

Q&A with Dr. David Diemert

 

Q&A with Dr. Manya Magnus

 

 


 

 

Dr. Moncef Slaoui outside of the GW COVID Vaccine Trailer

 

 

"Congratulations on a very well-run site. I also want to thank the volunteers at this particular site [and] the almost 30,000 participants in the Moderna trial, as well as the 45,000 volunteers in the Pfizer trial, who are taking a step to help show whether or not the vaccine works."

Dr. Moncef Slaoui
Chief Adviser, Operation Warp Speed

Oct. 21, 2020 GW press event

 

 60%

of GW's enrolled volunteers were male, 40% were female

2 Years

GW's vaccine research team will monitor trial volunteers

94.1%

vaccine efficacy against COVID-19 reported by Moderna

 

 


In the News 

Senior research assistant processes blood samples in the lab.

 

 

GW Plays Essential Role in COVID-19 Vaccine Approved for Emergency Use

December 17, 2020

The George Washington University was part of the historic nationwide effort to develop and test a safe, effective COVID-19 vaccine in record time, serving as a Phase 3 clinical trial site for the mRNA-1273 vaccine the Food and Drug Administration approved Friday for emergency use. The trial showed vaccine efficacy against COVID-19 to be 94.1 percent.

Moncef Slaoui, SMHS Dean Bass and SMHS professor David Diemert

 

 

Federal Government's COVID-19 Vaccine Trial Chief Visits GW Site

October 22, 2020

Moncef Slaoui, chief adviser for the U.S. Department of Health and Human Services’ COVID-19 vaccine development initiative, visited GW to raise awareness for the national vaccine development efforts, encourage greater participation in the clinical trials and recognize GW for exceeding its enrollment goals for its vaccine trial.

 

ABC News

 

 

The Washington Post

 

 

GWU's covid-19 clinical trial has met one early goal – getting Black and Latino people to join

September 13, 2020

Mark M. Spradley searched online for a vaccine clinical trial the way most people go shopping. Spradley, heeding an inner call to public duty, combed through the National Institutes of Health’s website and signed up for a trial underway at George Washington University because he was eager to become part of a massive, accelerated effort to develop a vaccine for the novel coronavirus that causes the disease covid-19.